Bausch + Lomb (BLCO) Projected to Post Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to issue its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $1.3694 billion for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last announced its earnings results on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 4.21%.The business’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.07) EPS. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Price Performance

BLCO opened at $16.24 on Monday. The company has a current ratio of 1.53, a quick ratio of 0.99 and a debt-to-equity ratio of 0.78. The company has a market cap of $5.80 billion, a price-to-earnings ratio of -26.19, a price-to-earnings-growth ratio of 0.50 and a beta of 0.56. The stock has a fifty day simple moving average of $15.88 and a two-hundred day simple moving average of $16.45. Bausch + Lomb has a 12-month low of $13.09 and a 12-month high of $18.92.

Wall Street Analyst Weigh In

Several research firms recently commented on BLCO. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Bausch + Lomb in a report on Thursday, April 30th. Citigroup boosted their price target on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Weiss Ratings upgraded Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $18.00.

Institutional Investors Weigh In On Bausch + Lomb

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after buying an additional 2,042 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after acquiring an additional 1,136 shares during the last quarter. Wells Fargo & Company MN increased its position in Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after acquiring an additional 1,403 shares during the last quarter. Focus Partners Wealth bought a new position in Bausch + Lomb in the third quarter valued at about $170,000. Finally, Invesco Ltd. bought a new position in Bausch + Lomb in the fourth quarter valued at about $178,000. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.